---
title: Reduce memory impairment using levetiracetam
nct_id: NCT04643327
phase: PHASE2
status: RECRUITING
sponsor: The University of Queensland
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT04643327"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04643327"
last_fetched: "2026-05-10T14:04:40.416Z"
source: "Parkinson's Pathways (curated)"
---
# Reduce memory impairment using levetiracetam

**Goal (in five words):** Reduce memory impairment using levetiracetam

**Official Title:** Double-blind Randomised-controlled Within-subject Crossover Trial to Determine Levetiracetam Efficacy for Memory Impairment in Parkinson's Disease: A Proof-of-concept Study

**Trial ID:** [NCT04643327](https://clinicaltrials.gov/study/NCT04643327)

## Key Facts

- **Phase:** PHASE2
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** The University of Queensland
- **Target Enrollment:** 28 participants
- **Start Date:** 2021-02-09
- **Completion Date:** 2025-01
- **Conditions:** Parkinson Disease, Mild Cognitive Impairment, Memory Impairment
- **Interventions:** Levetiracetam, Placebo
- **Intervention Types:** DRUG

## Summary For Families

Trying to see whether low-dose levetiracetam can reduce abnormal hippocampal activity and improve memory in people with Parkinson's who have amnestic mild cognitive impairment. Levetiracetam is an anticonvulsant that binds the synaptic vesicle protein SV2A to calm excess neuronal firing and normalize memory encoding, it does not act on dopamine pathways and is not expected to change levodopa metabolism, though it can cause mood or behavioral side effects and should not be used with other anticonvulsants. The trial is a double-blind, randomized within-subject crossover versus placebo with MRI assessments. They want people with Parkinson's with or without memory impairment plus healthy volunteers who can have MRI, and they exclude anyone with dementia, major psychiatric illness, current anticonvulsant use, severe renal impairment, or females of childbearing potential.

## Eligibility

- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Parkinson's Disease patients with amnestic Mild Cognitive Impairment
* Parkinson's Disease patients with no memory impairment
* Healthy volunteers
* All participants must be eligible to take MRI scans

Exclusion Criteria:

* Dementia
* Contraindication to having MRI
* Bipolar disorder, Schizophrenia, Alcohol or substance abuse
* Major depression
* Suicidal Ideation
* Difficulty complying with protocol requirements
* Significant non-PD neurological disease
* Vascular dementia
* Sensitivity to levetiracetam
* Use of anticonvulsant medications
* Use of other excluded medications
* Severe renal impairment
* Clinically significant abnormalities in B12 or thyroid function test (below normative range for elderly)
* Females of childbearing potential
```

## Locations (1)

- University of Queensland Centre for Clinical Research, Brisbane, Queensland, Australia _(-27.4679, 153.0281)_
  - Dana Pourzinal, BSc — (CONTACT) — 0733465028 — pd.research@uq.edu.au

---

*Canonical: https://parkinsonspathways.com/trial/NCT04643327*  
*HTML version: https://parkinsonspathways.com/trial/NCT04643327*  
*Source data: https://clinicaltrials.gov/study/NCT04643327*